ATE407947T1 - Proteine mit il-6 inhibitorischer wirkung - Google Patents

Proteine mit il-6 inhibitorischer wirkung

Info

Publication number
ATE407947T1
ATE407947T1 AT02804246T AT02804246T ATE407947T1 AT E407947 T1 ATE407947 T1 AT E407947T1 AT 02804246 T AT02804246 T AT 02804246T AT 02804246 T AT02804246 T AT 02804246T AT E407947 T1 ATE407947 T1 AT E407947T1
Authority
AT
Austria
Prior art keywords
proteins
inhibitory effect
medicianl
paritcular
seq
Prior art date
Application number
AT02804246T
Other languages
English (en)
Inventor
Jean-Yves Blay
Laurent Alberti
Original Assignee
Univ Claude Bernard Lyon
Ct Leon Berard
Inst Nat Sante Rech Med
Hospices Civils Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Claude Bernard Lyon, Ct Leon Berard, Inst Nat Sante Rech Med, Hospices Civils Lyon filed Critical Univ Claude Bernard Lyon
Application granted granted Critical
Publication of ATE407947T1 publication Critical patent/ATE407947T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02804246T 2001-12-04 2002-12-04 Proteine mit il-6 inhibitorischer wirkung ATE407947T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0115623A FR2833011B1 (fr) 2001-12-04 2001-12-04 Nouvelle proteine a activite inhibitrice de l'il-6

Publications (1)

Publication Number Publication Date
ATE407947T1 true ATE407947T1 (de) 2008-09-15

Family

ID=8870067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804246T ATE407947T1 (de) 2001-12-04 2002-12-04 Proteine mit il-6 inhibitorischer wirkung

Country Status (8)

Country Link
US (1) US7414024B2 (de)
EP (1) EP1451222B1 (de)
JP (1) JP2005524606A (de)
AT (1) ATE407947T1 (de)
AU (1) AU2002365646A1 (de)
DE (1) DE60228878D1 (de)
FR (1) FR2833011B1 (de)
WO (1) WO2003048205A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048210A1 (es) * 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
WO2007043641A1 (ja) * 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
KR101867606B1 (ko) * 2007-11-07 2018-06-18 제넨테크, 인크. 미생물 질환의 치료를 위한 조성물 및 방법
CA2728243C (en) 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
WO2011013786A1 (ja) * 2009-07-31 2011-02-03 Maeda Shin 癌の転移抑制剤
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3735421A4 (de) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. Verfahren zur behandlung von il-6-vermittelter entzündung ohne immunsuppression
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
EP3957324A4 (de) 2019-04-17 2023-02-08 Hiroshima University Therapeutikum für die urologische onkologie, dadurch gekennzeichnet, dass es in kombination mit il-6 -inhibitor und ccr2 -inhibitor verabreicht wird

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
WO1994019004A1 (en) * 1993-02-19 1994-09-01 Genentech, Inc. Ligand antagonists for treatment of breast cancer
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
WO1997010338A1 (en) * 1995-09-12 1997-03-20 Chiron Corporation Improved interleukin-6 receptor antagonist
EP0928293A1 (de) * 1996-06-20 1999-07-14 Koster, Henk W. Von il-6 und il-6 rezeptor abgeleitete peptide mit il-6 antagonistischer oder agonistischer aktivität
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system

Also Published As

Publication number Publication date
US7414024B2 (en) 2008-08-19
AU2002365646A1 (en) 2003-06-17
WO2003048205A3 (fr) 2004-01-22
EP1451222B1 (de) 2008-09-10
US20050158317A1 (en) 2005-07-21
FR2833011A1 (fr) 2003-06-06
JP2005524606A (ja) 2005-08-18
WO2003048205A2 (fr) 2003-06-12
DE60228878D1 (de) 2008-10-23
EP1451222A2 (de) 2004-09-01
FR2833011B1 (fr) 2004-10-29

Similar Documents

Publication Publication Date Title
ATE407947T1 (de) Proteine mit il-6 inhibitorischer wirkung
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
TR200200068T2 (tr) Nematisital triflüorobütenler
DE60235761D1 (de) Isoform des vegfs
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
ATE427116T1 (de) Behandlung von bakteriellen infektionen
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
MXPA02002119A (es) Productos leguminosos.
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
NO20010940D0 (no) TAN-1057 derivater
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE60225155D1 (de) 3-substituierte 6,7-dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
DE60208701D1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
DE60235132D1 (de) Sojaprodukte enthaltende Zusammensetzungen
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DK1051404T3 (da) Substituerede phenyluraciler med herbicid virkning
BR9808210A (pt) Befeniloxazolinas dissubstituìdas
UA91178C2 (ru) Мутантный неубластин
ATE241640T1 (de) Fusidinsäure-derivate
BR9611904A (pt) Dioxidos de ditiazol
WO2003072724A3 (en) Human analogs of murine deubiquitinating protease genes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties